DexCom Rallies After Earnings Beat, But Options Signal Caution

DXCM reported third-quarter results on October 29 and the market liked what it saw, with the stock rising nearly 3% the next day and closing the week up 5.6% at $82.29, a sharp reversal from the 8.4% drop flagged in the pre-earnings note published earlier this week.

The positioning story has shifted materially since that note. Short interest fell 8.6% over the week to around 14.7 million shares, now 3.8% of the free float, unwinding the pre-earnings build that had pushed it toward 4.1%. The borrow market remains completely unconstrained: availability is running at 3,330%, meaning the pool of shares available to lend is more than 33 times the shares currently borrowed. Cost to borrow has ticked up 30% over the week to 0.56%, which sounds notable in percentage terms but the absolute level is still negligible. The short score has also eased, falling from 38.6 at mid-October to 36.6, its lowest reading in recent weeks. Taken together, this is a market where the pre-earnings shorts have partially covered and no meaningful new wave of selling pressure has replaced them.

Options positioning is the one signal that cuts against the post-earnings relief. The put/call ratio closed Friday at 0.79, just under 2.5 standard deviations above its 20-day average of 0.73. That is a two-and-a-half-sigma reading, the most defensive options posture DXCM has carried in recent memory, and it arrived after the earnings beat rather than before it. One explanation is that the stock's 17% gap below the mean analyst price target of $96.96 is attracting hedgers who expect the recovery to be gradual rather than immediate. The analyst community moved quickly after the print: Barclays raised its target to $120 from $115 while maintaining Overweight, JP Morgan's Robbie Marcus lifted his target to $85 from $82 at Neutral, and StoneX moved to $93 from $82 at Buy. The direction across all three fresh actions is the same, higher targets, though the JP Morgan read is notably cautious given that even the raised target sits below the current price of $82.29 by just $2.73.

The broader analyst picture is constructive, with the consensus leaning to the buy side and multiple firms having raised targets through October. The factor scores add nuance: the analyst recommendation differential ranks in the 94th percentile of the ORTEX universe, confirming the Street skew toward positive ratings. EPS momentum and surprise scores are solid, both in the mid-to-high 60s. The weaker reads are on valuation, with EV/EBIT in the 33rd percentile and a price-to-earnings multiple of 26x that has come in roughly 2.4 points over the past month as the stock pulled back before earnings. The stock is not cheap, but it is cheaper than it was a month ago.

One macro risk worth tracking sits outside the earnings cycle entirely. ORTEX puts the probability of DXCM being deleted from the Nasdaq-100 at the December 2026 Annual Review at 62%. The mechanics are straightforward: at a $30.7 billion market cap, the company is 28.6% below the price level ($102.78) at which the index rule would flip the deletion call. The rank date is November 30, announcement expected December 11, with a trade date of December 18. If deletion were confirmed, index trackers would need to sell an estimated $2.5 billion of DXCM stock, equivalent to roughly 6.9 days of normal volume. In the 19 comparable past deletions tracked by ORTEX, the median move from announcement to effective date was minus 3.5%, with 79% of names moving in the expected direction and trade-day volume running at 7.4 times normal. A status-quo probability of 62% is not a certainty, and ORTEX puts it as a forecast rather than an announcement, but it is the single largest mechanical risk overhanging the stock into year-end.

Wikipedia attention for DexCom spiked around the earnings date, with the retail attention signal running at a z-score of 2.7 against its own 90-day history as of October 22. That kind of attention spike is typically earnings-related and transitory, but it confirms the print drew genuine public interest beyond the usual institutional audience. All-in, the post-earnings week leaves DXCM in an interesting middle ground: short sellers have retreated, the Street is incrementally more positive, yet options traders are hedging more aggressively than usual, and the Nasdaq-100 deletion clock is ticking toward its November 30 rank date.